Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Enveric

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results

Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.

EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline into a separate public company that will also be listed on the NASDAQ, and will be called Acanna Therapeutics Inc.

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach on April 19 for a full day of networking and education.

EXCLUSIVE: Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries

There were more than 30 different companies in the psychedelic space present at the inaugural Benzinga Psychedelics Capital Conference on Tuesday. But, Enveric is one of the only ones that offer investors exposure to both the psychedelic and cannabis space. Enveric Biosciences Inc (NASDAQ:

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.

Enveric Biosciences Reports Full-Year 2021 Financial Results

Enveric Biosciences Inc. (NASDAQ:ENVB) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Comprehensive net loss for the year was $48.8 million, including $36.3 million in net non-cash expenses, with a basic and diluted loss per share of $2.07, as compared to a comprehensive…

inkl

Read news from The Economist, FT, and more,
with one subscription

Five Companies Developing Second Generation Psychedelics For Mental Health

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. A new Johns Hopkins review study found that the positive effects of just two sessions of psilocybin-assisted psychotherapy can last for over one year in most patients with…

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary

Enveric Biosciences (NASDAQ: ENVB) a neuroscience company developing psychedelics and cannabinoids into mental health medicines, announced a collaboration with the University of Calgary’s Hotchkiss Brain Institute.

Enveric Biosciences Closes $10 Million Public Offering

Enveric Biosciences Closes $10 Million Public Offering

Psychedelics-based company Enveric Biosciences (NASDAQ: ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, befor

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis

Psychedelics and cannabinoid neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of two new molecular conjugates for osteoarthritis and other pain indications, which mix CBD with Celecoxib, a generic drug commonly prescribed for osteoarthritis.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Marijuana Moment

Field Trip Health

University of Calgary

Enveric Biosciences

Awakn Life Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

369,720 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play